The nanorobots—a collection of DNA molecules, some attached to antibodies —were designed to seek a specific set of human blood cells and attach a fluorescent tag to the cell surfaces. Details of the system were published July 28, 2013, in the online edition of Nature Nanotechnology.
This graphic shows a molecular robot (automaton) in action. To tag cells (grey circle) that display the Mi, Mj, and Mk receptors, five different components of a molecular robot are deployed. Each of the first three components consists of DNA and an antibody; one antibody binds to each receptor, bringing its DNA (represented by the colored lines) close together on the cell. The fourth DNA component, represented by the single red line, then initiates a chain reaction by pulling the red DNA strand away from the first antibody. That causes the blue DNA strand to change position, followed by the green DNA strand. In the final step, the last antibody pulls a fluorescent DNA strand (labeled F) from the fifth component, completing the action of the robot.
Credit: Milan Stojanovic, Ph.D./Columbia University Medical Center
"This opens up the possibility of using such molecules to target, treat, or kill specific cells without affecting similar healthy cells," said the study's senior investigator, Milan Stojanovic, PhD, associate professor of medicine and of biomedical engineering at Columbia University Medical Center. "In our experiment, we tagged the cells with a fluorescent marker; but we could replace that with a drug or with a toxin to kill the cell."
Though other DNA nanorobots have been designed to deliver drugs to cells, the advantage of Stojanovic's fleet is its ability to distinguish cell populations that do not share a single distinctive feature.
Cells, including cancer cells, rarely possess a single, exclusive feature that sets them apart from all other cells. This makes it difficult to design drugs without side effects. Drugs can be designed to target cancer cells with a specific receptor, but healthy cells with the same receptor will also be targeted.
The only way to target cells more precisely is to identify cells based on a collection of features. "If we look for the presence of five, six, or more proteins on the cell surface, we can be more selective," Dr. Stojanovic said. Large cell-sorting machines have the ability to identify cells based on multiple proteins, but until now, molecular therapeutics have not had that capability.How It Works
To identify a cell possessing three specific surface proteins, Dr. Stojanovic first constructed three different components for molecular robots. Each component consisted of a piece of double-stranded DNA attached to an antibody specific to one of the surface proteins. When these components are added to a collection of cells, the antibody portions of the robot bind to their respective proteins (in the figure, CD45, CD3, and CD8) and work in concert.
On cells where all three components are attached, a robot is functional and a fourth component (labeled 0 below) initiates a chain reaction among the DNA strands. Each component swaps a strand of DNA with another, until the end of the swap, when the last antibody obtains a strand of DNA that is fluorescently labeled.
At the end of the chain reaction—which takes less than 15 minutes in a sample of human blood—only cells with the three surface proteins are labeled with the fluorescent marker.
"We have demonstrated our concept with blood cells because their surface proteins are well known, but in principle our molecules could be deployed anywhere in the body," Dr. Stojanovic said. In addition, the system can be expanded to identify four, five, or even more surface proteins.
Now the researchers must show that their molecular robots work in a living animal; the next step will be experiments in mice.
This research was supported by the National Institutes of Health (R21CA128452, RC2CA147925, R21EB014477 and RGM104960), the National Science Foundation (CCF-0218262, CCF-0621600, ECCS-1026591, and CBET-1033288), the National Aeronautics and Space Administration (NAS2-02039), and the Lymphoma and Leukemia Foundation.
The researchers declare no financial or other conflicts of interests.
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.
Karin Eskenazi | EurekAlert!
Molecular doorstop could be key to new tuberculosis drugs
20.03.2018 | Rockefeller University
Modified biomaterials self-assemble on temperature cues
20.03.2018 | Duke University
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
20.03.2018 | Earth Sciences
20.03.2018 | Physics and Astronomy
20.03.2018 | Information Technology